When facing thousands of listed company announcements every day, which ones should you read? What are the key points to take away from the dozens or hundreds of pages of material announcements? Are the many professional terms in the announcements bullish or bearish? Check out Caixin's "Quick Read Announcement" column, where our reporters across the country will provide you with accurate, fast and professional interpretations on the night of the announcement.

Financial Associated Press, October 23rd (Reporter Lu A Feng) Livzon Pharmaceutical Group Inc. (000513.SZ) is still under pressure in terms of performance, will Simvastatin become a solution?

Today, Livzon Pharmaceutical Group Inc. released its third quarter report, achieving a revenue of 9.082 billion yuan in the first three quarters, a decrease of 5.94% year-on-year, and achieving a net profit attributable to the parent company of 1.673 billion yuan, an increase of 4.44% year-on-year. In Q3 alone, Livzon Pharmaceutical Group Inc. achieved a revenue of 2.799 billion yuan, a decrease of 5.59% year-on-year, and achieved a net profit attributable to the parent company of 0.502 billion yuan, an increase of 7.45% year-on-year.

Among them, the revenue contribution of the pharmaceutical sector, which ranks first in Livzon Pharmaceutical Group Inc., achieved a revenue of 4.714 billion yuan, a decrease of 8.52% year-on-year. Among them, the revenue of gastrointestinal products was 1.854 billion yuan, a decrease of 18.66% year-on-year; the revenue of sex hormone products was 2.308 billion yuan, an increase of 5.46% year-on-year; the revenue of mental health products was 0.443 billion yuan, an increase of 3.11% year-on-year; and the revenue of anti-infective and other products was 0.109 billion yuan, a decrease of 57.32% year-on-year.

The better performing sectors are the biological product sector and the diagnostic sector. In the first three quarters of this year, the biological product sector achieved a revenue of 0.131 billion yuan, an increase of 15.98% year-on-year; the revenue of diagnostic reagents and equipment products was 0.566 billion yuan, an increase of 21.03% year-on-year.

Financial Associated Press reporters found that the performance of Livzon Pharmaceutical Group Inc. this time did not change much compared to the trend shown in its H1 financial report. At a previous earnings conference, the management of Livzon Pharmaceutical Group Inc. explained that due to factors such as national price negotiations of products and centralized procurement of some products, the revenue of gastrointestinal products decreased by 19.96% year-on-year, dragging down the company's revenue in the chemical preparation sector in the first half of the year. The traditional chinese medicine preparations sector suffered a significant impact due to the high base effects of the flu and COVID-19 in the same period last year, with the antiviral granules being significantly affected, resulting in a year-on-year decrease in revenue in H1 this year. The diagnostic reagents and equipment sector saw an accelerated growth in sales of respiratory products and major infectious disease products, leading to an increase in revenue year-on-year.

Yang Liang, the Secretary of the Board of Directors of Livzon Pharmaceutical Group Inc., once said at the earnings conference mentioned above, "There was some pressure on performance in the first half of this year. It is expected that the performance will gradually improve in the third and fourth quarters of this year, and the profit for the whole year will strive to maintain stable growth."

From the perspective of Q3 revenue and net profit performance, the performance of Livzon Pharmaceutical Group Inc. has improved to a certain extent.

It is worth mentioning that as one of the domestic GLP-1 concept stocks, Livzon Pharmaceutical Group Inc. submitted the listing application for semaglutide for adult type 2 diabetes in June this year, and the weight loss indication has initiated Phase III clinical trials.

Undoubtedly, GLP-1 is a hot topic in the current biomedical industry. At an investor communication meeting in September, Livzon Pharmaceutical Group Inc. stated that the company's research and development progress is fast, with a clear time progress advantage. At the same time, the company has had research and production of complex raw materials such as acarbose. Based on the long-term advantages in fermentation raw material technology accumulation, the company currently possesses a stable production process level and capability in semaglutide active pharmaceutical ingredient and formulation, and will continue to accelerate subsequent research and development progress.